https://www.biopharmawatch.com/news/RVPH/reviva-reports-q3-2026-results-business-highlights BiopharmaWatch en 2026-11-13T01:13:00.000Z Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-pricing-public-offering-common-stock BiopharmaWatch en 2026-11-13T00:38:00.000Z Vir Biotechnology Announces Pricing of Public Offering of Common Stock https://www.biopharmawatch.com/news/CLLS/cellectis-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-13T00:24:00.000Z Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/BIIB/leqembi-pen-launch-japan-alzheimers BiopharmaWatch en 2026-11-12T23:30:48.000Z LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease https://www.biopharmawatch.com/news/BKD/brookdale-present-stephens-investment-conference-2026 BiopharmaWatch en 2026-11-12T22:45:00.000Z Brookdale to Present at the 2026 Stephens Annual Investment Conference | NASH2026 https://www.biopharmawatch.com/news/CTSO/cytosorbents-q3-2026-financial-results-update BiopharmaWatch en 2026-11-12T22:16:00.000Z CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update https://www.biopharmawatch.com/news/REGN/regeneron-baloncibart-pots-phase-2-trial-results BiopharmaWatch en 2026-11-12T22:00:00.000Z POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-inducement-grants-nasdaq BiopharmaWatch en 2026-11-12T22:00:00.000Z Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/LGVN/longeveron-q3-2026-financial-results-update BiopharmaWatch en 2026-11-12T21:54:00.000Z Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-12T21:35:00.000Z Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/CGEM/nda-submission-zipalertinib-nsclc BiopharmaWatch en 2026-11-12T21:30:12.000Z New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-q3-2026-results-update BiopharmaWatch en 2026-11-12T21:30:00.000Z Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-12T21:30:00.000Z DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/MANE/veradermics-presentation-jefferies-conference-london BiopharmaWatch en 2026-11-12T21:30:00.000Z Veradermics to Present at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/ZYBT/zhengye-biotechnology-financial-results-fy2026 BiopharmaWatch en 2026-11-12T21:30:00.000Z Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026 https://www.biopharmawatch.com/news/AZTR/azitra-announces-q3-2026-results-business-updates BiopharmaWatch en 2026-11-12T21:30:00.000Z Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates https://www.biopharmawatch.com/news/AEMD/aethlon-medical-q2-fiscal-2027-results-update BiopharmaWatch en 2026-11-12T21:30:00.000Z Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update https://www.biopharmawatch.com/news/HIT/health-in-tech-reports-q3-2026-results BiopharmaWatch en 2026-11-12T21:30:00.000Z Health In Tech Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PRAX/praxis-launch-readiness-relutrigine-ulixacaltamide BiopharmaWatch en 2026-11-12T21:30:00.000Z Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day https://www.biopharmawatch.com/news/STRO/sutro-biopharma-q3-2026-results-highlights BiopharmaWatch en 2026-11-12T21:30:00.000Z Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/YDES/yd-bio-fda-interact-meeting-ydb-lmscev-001 BiopharmaWatch en 2026-11-12T21:30:00.000Z YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease https://www.biopharmawatch.com/news/SER/serina-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-12T21:20:00.000Z Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/BCDA/biocardia-reports-q3-2026-results BiopharmaWatch en 2026-11-12T21:19:00.000Z BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results https://www.biopharmawatch.com/news/RPRX/royalty-pharma-ubs-global-biopharma-conference BiopharmaWatch en 2026-11-12T21:18:15.000Z Royalty Pharma to present at the UBS Global Biopharma Conference https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-12T21:16:00.000Z Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NBTX/nanobiotix-voting-rights-share-capital BiopharmaWatch en 2026-11-12T21:15:27.000Z Voting Rights and Shares Capital of the Company https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-announces-closing-existing-warrants-exercise-3-0-million BiopharmaWatch en 2026-11-12T21:15:00.000Z Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-q3-2026-results BiopharmaWatch en 2026-11-12T21:15:00.000Z Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/A/agilent-participate-evercore-healthcare-conference BiopharmaWatch en 2026-11-12T21:15:00.000Z Agilent to Participate in 9th Annual Evercore Healthcare Conference https://www.biopharmawatch.com/news/ARDT/ardent-health-acquires-boone-health BiopharmaWatch en 2026-11-12T21:15:00.000Z Ardent Health Announces Definitive Agreement to Acquire Boone Health https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-12T21:15:00.000Z Nektar Therapeutics Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ENOV/enovis-presents-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-12T21:15:00.000Z Enovis to Present at the Annual Jefferies Global Healthcare Concerence in London https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-q3-2026-results-highlights BiopharmaWatch en 2026-11-12T21:15:00.000Z Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/IMMX/immix-biopharma-q3-2026-financial-results-update BiopharmaWatch en 2026-11-12T21:15:00.000Z Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress https://www.biopharmawatch.com/news/ANAB/anaptys-reports-fiscal-first-quarter-2027-results BiopharmaWatch en 2026-11-12T21:15:00.000Z Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/BGMS/bio-green-med-solution-third-quarter-results BiopharmaWatch en 2026-11-12T21:15:00.000Z BIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE https://www.biopharmawatch.com/news/NSPR/inspiremd-proposed-public-offering BiopharmaWatch en 2026-11-12T21:15:00.000Z InspireMD Announces Proposed Public Offering https://www.biopharmawatch.com/news/PRME/prime-medicine-public-offering-closure BiopharmaWatch en 2026-11-12T21:15:00.000Z Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/VNRX/volitionrx-q3-2026-financial-results-update BiopharmaWatch en 2026-11-12T21:10:00.000Z VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/RNA/atrium-therapeutics-reports-q3-2026-results BiopharmaWatch en 2026-11-12T21:10:00.000Z Atrium Therapeutics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PROK/prokidney-reports-q3-2026-results BiopharmaWatch en 2026-11-12T21:10:00.000Z ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/SMTI/sanara-medtech-third-quarter-2026-results BiopharmaWatch en 2026-11-12T21:10:00.000Z Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited) https://www.biopharmawatch.com/news/VIR/vir-biotechnology-announces-proposed-public-offering BiopharmaWatch en 2026-11-12T21:08:00.000Z Vir Biotechnology Announces Proposed Public Offering https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-12T21:05:57.000Z Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform https://www.biopharmawatch.com/news/DYAI/dyadic-announces-q3-2026-results BiopharmaWatch en 2026-11-12T21:05:41.000Z Dyadic Announces Third Quarter 2026 Financial Results and Recent Developments https://www.biopharmawatch.com/news/STEX/streamex-reports-q3-2026-results BiopharmaWatch en 2026-11-12T21:05:38.000Z Streamex Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-q3-2026-results-update BiopharmaWatch en 2026-11-12T21:05:00.000Z SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q3-2026-results-business-update BiopharmaWatch en 2026-11-12T21:05:00.000Z Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-present-upcoming-conference BiopharmaWatch en 2026-11-12T21:05:00.000Z Iovance Biotherapeutics to Present at Upcoming Conference https://www.biopharmawatch.com/news/EVMN/evommune-reports-q3-2026-results-business-highlights BiopharmaWatch en 2026-11-12T21:05:00.000Z Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/NPCE/neuropace-reports-third-quarter-2026-financial-results-provides-revised-full BiopharmaWatch en 2026-11-12T21:05:00.000Z NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance https://www.biopharmawatch.com/news/OBX/obsidian-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-12T21:05:00.000Z Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q3-2026-results BiopharmaWatch en 2026-11-12T21:05:00.000Z Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-12T21:05:00.000Z Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-q3-2026-results-update BiopharmaWatch en 2026-11-12T21:05:00.000Z Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update https://www.biopharmawatch.com/news/BSEM/biostem-technologies-q3-2026-financial-results BiopharmaWatch en 2026-11-12T21:05:00.000Z BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio https://www.biopharmawatch.com/news/PMN/promis-neurosciences-q3-2026-results BiopharmaWatch en 2026-11-12T21:05:00.000Z ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-reports-third-quarter-2026-financial-results-provides-business BiopharmaWatch en 2026-11-12T21:05:00.000Z Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/STTK/shattuck-labs-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-11-12T21:05:00.000Z Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/RKDA/arcadia-biosciences-q3-2026-results BiopharmaWatch en 2026-11-12T21:05:00.000Z Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/SCTX/scribe-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-12T21:05:00.000Z Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/GUTS/fractyl-health-q3-2026-results-updates BiopharmaWatch en 2026-11-12T21:05:00.000Z Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/EQ/equillium-reports-q3-2026-results-eq504-trial-update BiopharmaWatch en 2026-11-12T21:05:00.000Z Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights https://www.biopharmawatch.com/news/CV/capso-vision-reports-q3-2026-results BiopharmaWatch en 2026-11-12T21:05:00.000Z CapsoVision Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ADRX/adarx-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-12T21:05:00.000Z ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/FDMT/4dmt-reports-q3-2026-results-and-milestones BiopharmaWatch en 2026-11-12T21:05:00.000Z 4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-12T21:05:00.000Z Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/SVRA/savara-inducement-grant-new-employees BiopharmaWatch en 2026-11-12T21:05:00.000Z Savara Announces New Employment Inducement Grant https://www.biopharmawatch.com/news/LFMD/lifemd-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-12T21:05:00.000Z LifeMD Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/ICCC/immucell-financial-results-q3-2026 BiopharmaWatch en 2026-11-12T21:05:00.000Z ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/CADL/candel-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-12T21:05:00.000Z Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/PLRX/pliant-therapeutics-update-q3-2026-results BiopharmaWatch en 2026-11-12T21:05:00.000Z Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALMS/alumis-q3-2026-financial-results-business-updates BiopharmaWatch en 2026-11-12T21:05:00.000Z Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates https://www.biopharmawatch.com/news/AZR/azora-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-12T21:05:00.000Z Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update https://www.biopharmawatch.com/news/NSPR/inspiremd-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-12T21:03:07.000Z InspireMD Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LCTX/lineage-acquires-neuroairmid-therapeutics-huntingtons-disease BiopharmaWatch en 2026-11-12T21:03:00.000Z Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease https://www.biopharmawatch.com/news/MTEX/mannatech-financial-results-q3-2026 BiopharmaWatch en 2026-11-12T21:02:00.000Z Mannatech Reports Financial Results for Third Quarter 2026 https://www.biopharmawatch.com/news/NCNA/nucana-reports-q3-2026-results-and-update BiopharmaWatch en 2026-11-12T21:01:50.000Z NuCana Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-2026-fiscal-year-results BiopharmaWatch en 2026-11-12T21:01:00.000Z Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results https://www.biopharmawatch.com/news/BEAT/heartbeam-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-12T21:01:00.000Z HeartBeam Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261112 BiopharmaWatch en 2026-11-12T21:01:00.000Z Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/TLPH/talphera-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-12T21:01:00.000Z Talphera Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CRIS/curis-third-quarter-2026-business-update BiopharmaWatch en 2026-11-12T21:01:00.000Z Curis Provides Third Quarter 2026 Business Update https://www.biopharmawatch.com/news/ERAS/erasca-q3-2026-business-updates-results BiopharmaWatch en 2026-11-12T21:01:00.000Z Erasca Reports Third Quarter 2026 Business Updates and Financial Results https://www.biopharmawatch.com/news/BDTX/black-diamond-therapeutics-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-12T21:01:00.000Z Black Diamond Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PRME/prime-medicine-q3-2026-results-updates BiopharmaWatch en 2026-11-12T21:01:00.000Z Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-q3-2026-financial-results BiopharmaWatch en 2026-11-12T21:01:00.000Z NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update https://www.biopharmawatch.com/news/MGNX/macrogenics-reports-q3-2026-results BiopharmaWatch en 2026-11-12T21:01:00.000Z MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress https://www.biopharmawatch.com/news/HTFL/heartflow-reports-q3-2026-results-guidance BiopharmaWatch en 2026-11-12T21:01:00.000Z Heartflow Reports Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance https://www.biopharmawatch.com/news/ENSG/ensign-group-presentation-stephens-conference-2026 BiopharmaWatch en 2026-11-12T21:01:00.000Z The Ensign Group to Present at the Stephens Annual Investment Conference on November 18, 2026 https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-12T21:01:00.000Z BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/ETRA/electra-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-12T21:01:00.000Z Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights https://www.biopharmawatch.com/news/BMEA/biomea-fusion-participate-upcoming-investor-conferences-20261112 BiopharmaWatch en 2026-11-12T21:01:00.000Z Biomea Fusion to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/DERM/journey-medical-q3-2026-results BiopharmaWatch en 2026-11-12T21:01:00.000Z Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/NSPR/inspiremd-fda-approval-cguard-prime-tcar BiopharmaWatch en 2026-11-12T21:01:00.000Z InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-reports-q3-2026-results BiopharmaWatch en 2026-11-12T21:00:00.000Z Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress https://www.biopharmawatch.com/news/KOD/kodiak-sciences-q3-2026-financial-results BiopharmaWatch en 2026-11-12T21:00:00.000Z Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OGEN/oragenics-nyse-compliance-plan-extension-2028 BiopharmaWatch en 2026-11-12T21:00:00.000Z Oragenics Receives NYSE American Approval of Compliance Plan and Extension Through February 2028 https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-reports-q3-2026-results BiopharmaWatch en 2026-11-12T21:00:00.000Z Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates https://www.biopharmawatch.com/news/MDXH/mdxhealth-third-quarter-2026-results BiopharmaWatch en 2026-11-12T21:00:00.000Z Mdxhealth Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LLY/lilly-pennsylvania-lehigh-valley-manufacturing-site BiopharmaWatch en 2026-11-12T20:30:00.000Z Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020 https://www.biopharmawatch.com/news/SNY/sanofi-voting-rights-and-shares-october-2026 BiopharmaWatch en 2026-11-12T17:30:00.000Z Sanofi: Information concerning the total number of voting rights and shares - October 2026 https://www.biopharmawatch.com/news/EMMA/emmaus-life-sciences-middle-east-strategy BiopharmaWatch en 2026-11-12T17:14:00.000Z Emmaus Life Sciences Advances Middle East Strategy with Real-World Evidence Initiatives and Expansion into Africa https://www.biopharmawatch.com/news/CLNN/clene-nanomedicine-veristat-als-drug-application BiopharmaWatch en 2026-11-12T17:09:00.000Z Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application https://www.biopharmawatch.com/news/NVS/rhapsido-phase-iii-data-cindu BiopharmaWatch en 2026-11-12T16:57:00.000Z New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU) https://www.biopharmawatch.com/news/EYE/nemours-childrens-health-pediatric-care-home-conference BiopharmaWatch en 2026-11-12T15:54:00.000Z Nemours Children's Health Brings Leading Industry Experts Together to Advance National Vision for Pediatric Care in the Home Setting https://www.biopharmawatch.com/news/PHVS/pharvaris-clinical-data-acaa-2026 BiopharmaWatch en 2026-11-12T15:28:00.000Z Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting https://www.biopharmawatch.com/news/NTHI/neonc-ceo-buys-shares-fda-meeting-phase-3-trial BiopharmaWatch en 2026-11-12T15:13:00.000Z NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial https://www.biopharmawatch.com/news/IONS/ionis-donidalorsen-data-acaa-2026 BiopharmaWatch en 2026-11-12T15:00:00.000Z Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting https://www.biopharmawatch.com/news/DBVT/dbv-technologies-vitesse-phase-3-study-viaskin-peanut-patch BiopharmaWatch en 2026-11-12T15:00:00.000Z DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years https://www.biopharmawatch.com/news/NTLA/intellia-lonvoguran-ziclumeran-acaa-2026 BiopharmaWatch en 2026-11-12T15:00:00.000Z Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026 https://www.biopharmawatch.com/news/NMAD/nomad-supply-chain-production-ramp-utility-rfps-rise BiopharmaWatch en 2026-11-12T14:38:00.000Z NOMAD Firms Up Supply Chain for Q1 2027 Production Ramp as Utility RFPs Rise 150% Quarter-over-Quarter https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-q3-2026-results BiopharmaWatch en 2026-11-12T14:25:00.000Z Healthcare Triangle Reports Third Quarter 2026 Results: Nine-Month Revenue Up 162% to $28.2 Million and Nine-Month Gross Margin Up 354% https://www.biopharmawatch.com/news/NTHI/neonc-insider-buying-fda-discussions-brain-cancer BiopharmaWatch en 2026-11-12T14:24:00.000Z NeOnc Insider Buying Expands Ahead of FDA Discussions and Two Key Brain Cancer Data Presentations https://www.biopharmawatch.com/news/WRBY/warby-parker-intelligent-eyewear-preorders BiopharmaWatch en 2026-11-12T14:00:00.000Z Warby Parker Opens Preorders for First Intelligent Eyewear Collection https://www.biopharmawatch.com/news/CVS/cvs-launches-caliber-artist-series-journals BiopharmaWatch en 2026-11-12T14:00:00.000Z CVS Pharmacy® launches latest collection of Caliber® Artist Series colleague-designed journals https://www.biopharmawatch.com/news/OLMA/olema-oncology-announces-name-change BiopharmaWatch en 2026-11-12T14:00:00.000Z Olema Oncology Announces Corporate Name Change https://www.biopharmawatch.com/news/MBRX/moleculin-australian-patent-annamycin-technology BiopharmaWatch en 2026-11-12T13:52:27.000Z Moleculin Secures Australian Patent for Annamycin Formulation Technology https://www.biopharmawatch.com/news/ALPS/alps-group-launches-pharmaco-interaction-unit BiopharmaWatch en 2026-11-12T13:45:29.000Z Alps Group Inc Launches Pharmaco-Interaction (PCI) Unit via MyGenome, Debuting with CYP450 Drug Interaction Testing https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-expands-hsa-fsa-payment-option BiopharmaWatch en 2026-11-12T13:32:00.000Z Niagen Bioscience Expands HSA/FSA Payment Option for the Pharmaceutical-Grade Niagen™ At-Home Injection Kit through Niagen™ Plus https://www.biopharmawatch.com/news/MTVA/metavia-phase-1-da-1726-uric-acid-reduction BiopharmaWatch en 2026-11-12T13:31:00.000Z MetaVia Announces Statistically Significant Reduction in Uric Acid Levels with DA-1726 in Phase 1 Part 3B Clinical Trial https://www.biopharmawatch.com/news/DRTS/alpha-tau-investor-call-regain-trial-data BiopharmaWatch en 2026-11-12T13:30:00.000Z Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial https://www.biopharmawatch.com/news/SLGL/sol-gel-reports-q3-2026-results-and-updates BiopharmaWatch en 2026-11-12T13:30:00.000Z Sol-Gel Reports Third Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/TDOC/teladoc-health-canada-strategic-innovation-partner BiopharmaWatch en 2026-11-12T13:30:00.000Z Teladoc Health Canada Named Strategic Innovation Partner by NL Health Services to Advance Virtual Care Across the Province https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-health-canada-approvals-tslim-x2 BiopharmaWatch en 2026-11-12T13:30:00.000Z Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump https://www.biopharmawatch.com/news/GILD/gilead-hiv-prevention-latin-grammy-awards BiopharmaWatch en 2026-11-12T13:30:00.000Z Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards® https://www.biopharmawatch.com/news/FBLG/fibrobiologics-update-intellectual-property-portfolio BiopharmaWatch en 2026-11-12T13:30:00.000Z FibroBiologics Announces Update On Its Intellectual Property Portfolio https://www.biopharmawatch.com/news/AMIX/autonomix-renal-denervation-strategy-tct-2026 BiopharmaWatch en 2026-11-12T13:30:00.000Z Autonomix Highlights Renal Denervation Strategy and Vision for Illuminating the Nervous System at TCT 2026 https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-whitepaper-nocad-detection BiopharmaWatch en 2026-11-12T13:25:00.000Z Cardio Diagnostics’ Whitepaper Examines Clinical Blind Spot in Coronary Heart Disease Detection and Care https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-q3-2026-results BiopharmaWatch en 2026-11-12T13:00:38.000Z MeiraGTx Reports Third Quarter 2026 Financial and Operational Results https://www.biopharmawatch.com/news/ECOR/non-invasive-autonomic-neuromodulation-long-covid BiopharmaWatch en 2026-11-12T13:00:00.000Z Randomized Study of Non-Invasive Autonomic Neuromodulation for Long COVID Published Online in Neuromodulation https://www.biopharmawatch.com/news/CLGN/collplant-begin-trading-nasdaq-new-ticker-ophi BiopharmaWatch en 2026-11-12T13:00:00.000Z CollPlant to Begin Trading on Nasdaq Under New Ticker Symbol “OPHI” https://www.biopharmawatch.com/news/CRL/charles-river-global-microbial-solutions-investments BiopharmaWatch en 2026-11-12T13:00:00.000Z Charles River Strengthens Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability https://www.biopharmawatch.com/news/SLN/silence-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-12T13:00:00.000Z Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-business-update-q3-2026 BiopharmaWatch en 2026-11-12T13:00:00.000Z Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ATNM/actinium-webinar-atnm-400-her3-targeted-therapy BiopharmaWatch en 2026-11-12T13:00:00.000Z Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy https://www.biopharmawatch.com/news/VTRS/viatris-named-fortunes-best-workplaces-2026 BiopharmaWatch en 2026-11-12T13:00:00.000Z Viatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive Year https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-q2-2027-financial-results BiopharmaWatch en 2026-11-12T13:00:00.000Z Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update https://www.biopharmawatch.com/news/ANVS/annovis-bio-patent-buntanetap-crystalline-form BiopharmaWatch en 2026-11-12T13:00:00.000Z Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-present-jefferies-global-healthcare-conference-2026-london BiopharmaWatch en 2026-11-12T13:00:00.000Z Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London https://www.biopharmawatch.com/news/AVLN/avalyn-reports-q3-2026-results-business-highlights BiopharmaWatch en 2026-11-12T13:00:00.000Z Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/VANI/vivani-medical-positive-results-slim-1-trial BiopharmaWatch en 2026-11-12T13:00:00.000Z Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-11-12T13:00:00.000Z Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results https://www.biopharmawatch.com/news/AKTS/aktis-oncology-q3-results-clinical-trial-progress BiopharmaWatch en 2026-11-12T13:00:00.000Z Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-bla-submission-miv-cel-sps BiopharmaWatch en 2026-11-12T13:00:00.000Z Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-12T13:00:00.000Z Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/IMNN/imunon-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-12T13:00:00.000Z IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/TOVX/theriva-biologics-q3-2026-results BiopharmaWatch en 2026-11-12T13:00:00.000Z Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results https://www.biopharmawatch.com/news/BDMD/baird-medical-enters-south-korea-market BiopharmaWatch en 2026-11-12T13:00:00.000Z Baird Medical Enters South Korea Market through Strategic Distribution Partnership with ALLIS MED https://www.biopharmawatch.com/news/EVAX/evaxion-2027-financial-calendar BiopharmaWatch en 2026-11-12T13:00:00.000Z Evaxion announce 2027 financial calendar https://www.biopharmawatch.com/news/TAK/takeda-launches-orzeyful-oveporexton-narcolepsy-type-1 BiopharmaWatch en 2026-11-12T12:35:00.000Z Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States https://www.biopharmawatch.com/news/VOR/vor-bio-expands-partnership-remegen-rc298 BiopharmaWatch en 2026-11-12T12:30:39.000Z Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise https://www.biopharmawatch.com/news/DYAI/dyadic-c1-produced-antibodies-animal-studies BiopharmaWatch en 2026-11-12T12:30:33.000Z Dyadic’s C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations https://www.biopharmawatch.com/news/ASND/ascendis-pharma-q3-2026-financial-results BiopharmaWatch en 2026-11-12T12:30:00.000Z Ascendis Pharma Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMRX/immuneering-collaborates-with-astellas-on-clinical-studies BiopharmaWatch en 2026-11-12T12:30:00.000Z Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-12T12:30:00.000Z Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/IMRX/immuneering-phase-2-trial-atebimetinib-anaplastic-thyroid-cancer BiopharmaWatch en 2026-11-12T12:30:00.000Z Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer https://www.biopharmawatch.com/news/CNSY/cerenome-review-reyobiq-respect-lm-data-update BiopharmaWatch en 2026-11-12T12:30:00.000Z Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16 https://www.biopharmawatch.com/news/ALT/altimmune-third-quarter-2026-results-update BiopharmaWatch en 2026-11-12T12:30:00.000Z Altimmune Announces Third Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-q3-2026-update BiopharmaWatch en 2026-11-12T12:30:00.000Z Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-12T12:30:00.000Z Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/PFSA/profusa-progress-option-agreement-g3 BiopharmaWatch en 2026-11-12T12:30:00.000Z Profusa Announces Progress Towards Satisfying the Conditions to Close of the Option Agreement with G3 https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-11-12T12:30:00.000Z Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/GENB/generate-biomedicines-inc-reports-second-third-2026-financial-results-provides BiopharmaWatch en 2026-11-12T12:21:37.000Z Generate Biomedicines Inc. Reports Second Third 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/GENB/generate-biomedicines-q3-2026-results-update BiopharmaWatch en 2026-11-12T12:20:00.000Z Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/TWST/twist-bioscience-fiscal-2026-results BiopharmaWatch en 2026-11-12T12:15:00.000Z Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results https://www.biopharmawatch.com/news/NGEN/nervgen-fda-breakthrough-therapy-nvg-291 BiopharmaWatch en 2026-11-12T12:15:00.000Z NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury https://www.biopharmawatch.com/news/ALT/altimmune-impact-phase-2b-48-week-data-mash BiopharmaWatch en 2026-11-12T12:15:00.000Z Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology https://www.biopharmawatch.com/news/ABSI/absci-reports-business-updates-q3-2026-results BiopharmaWatch en 2026-11-12T12:05:50.000Z Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/IPSC/century-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-12T12:05:00.000Z Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-presentation-bell-potter-conference BiopharmaWatch en 2026-11-12T12:05:00.000Z Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-announces-participation-renmark-financial-communications-virtual-non BiopharmaWatch en 2026-11-12T12:01:33.000Z Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-q3-2026-results-update BiopharmaWatch en 2026-11-12T12:01:00.000Z Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update https://www.biopharmawatch.com/news/ABSI/absci-appoints-gerry-muhle-as-cfo BiopharmaWatch en 2026-11-12T12:00:24.000Z Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline https://www.biopharmawatch.com/news/TLRY/portland-trail-blazers-craft-beer-partners BiopharmaWatch en 2026-11-12T12:00:20.000Z 10 Barrel Brewing, Widmer Brothers and Hop Valley Named Official Craft Beer Partners of the Portland Trail Blazers https://www.biopharmawatch.com/news/KPRX/kiora-pharmaceuticals-q3-2026-results-update BiopharmaWatch en 2026-11-12T12:00:00.000Z Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/PRQR/proqr-announces-q3-2026-results BiopharmaWatch en 2026-11-12T12:00:00.000Z ProQR Announces Third Quarter 2026 Operating and Financial Results https://www.biopharmawatch.com/news/MRNA/moderna-growth-strategy-analyst-day-2026 BiopharmaWatch en 2026-11-12T12:00:00.000Z Moderna Outlines Next Phase of Growth at Analyst Day https://www.biopharmawatch.com/news/YARW/yarrow-bioscience-q3-2026-results-update BiopharmaWatch en 2026-11-12T12:00:00.000Z Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/KARD/kardigan-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-12T12:00:00.000Z Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates https://www.biopharmawatch.com/news/CSTL/castle-biosciences-earns-2026-top-workplaces-awards-recognizing-people-first BiopharmaWatch en 2026-11-12T12:00:00.000Z Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture https://www.biopharmawatch.com/news/HROW/harrow-participate-investor-conferences-november BiopharmaWatch en 2026-11-12T12:00:00.000Z Harrow to Participate in Two Investor Conferences in November https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-12T12:00:00.000Z EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-12T12:00:00.000Z TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/OKYO/okyo-pharma-2026-jefferies-conference-london BiopharmaWatch en 2026-11-12T12:00:00.000Z OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/TRAW/traws-pharma-final-phase-2a-results-ratutrelvir BiopharmaWatch en 2026-11-12T12:00:00.000Z Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID® https://www.biopharmawatch.com/news/MGRX/mangoceuticals-tokenized-preferred-stock-t7x BiopharmaWatch en 2026-11-12T12:00:00.000Z Mangoceuticals Partners with T7X to Become the First Nasdaq-Listed Company to Offer Tokenized Preferred Stock on the T7X Platform https://www.biopharmawatch.com/news/HYPD/hyperion-defi-q3-2026-financial-results BiopharmaWatch en 2026-11-12T12:00:00.000Z Hyperion DeFi Reports Q3 2026 Financial Results with Third Consecutive Quarterly Record Net Income, Achieving Breakeven Guidance on Core Operations and Cash Flows https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-q3-2026-financial-results BiopharmaWatch en 2026-11-12T12:00:00.000Z Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-q3-2026-results-business-update BiopharmaWatch en 2026-11-12T12:00:00.000Z Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-12T12:00:00.000Z Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-q3-2026-results BiopharmaWatch en 2026-11-12T12:00:00.000Z American Shared Hospital Services Reports Third Quarter and Nine-Month 2026 Financial Results https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-advocate-health-joint-venture-illinois BiopharmaWatch en 2026-11-12T12:00:00.000Z Lumexa Imaging Expands Partnership with Advocate Health Through New Illinois Joint Venture https://www.biopharmawatch.com/news/MSLE/satellos-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-12T12:00:00.000Z Satellos Reports Third Quarter 2026 Financial Results and Highlights Company Progress https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-q3-results-2026 BiopharmaWatch en 2026-11-12T12:00:00.000Z Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2026 Guidance https://www.biopharmawatch.com/news/MDWD/mediwound-reports-q3-2026-results-update BiopharmaWatch en 2026-11-12T12:00:00.000Z MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-virtual-event-nd2-oncology BiopharmaWatch en 2026-11-12T12:00:00.000Z Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader https://www.biopharmawatch.com/news/CANF/can-fites-piclidenoson-kidney-disease-lowe-syndrome-study BiopharmaWatch en 2026-11-12T12:00:00.000Z Can-Fite's Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study: Published in Nature Portfolio Journal https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-research-development-evolution BiopharmaWatch en 2026-11-12T11:59:00.000Z Bristol Myers Squibb Announces Evolution of Research & Development Organization https://www.biopharmawatch.com/news/PHVS/pharvaris-q3-2026-financial-results-business-update BiopharmaWatch en 2026-11-12T11:50:00.000Z Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MRK/merck-participate-jefferies-global-healthcare-conference-london BiopharmaWatch en 2026-11-12T11:45:00.000Z Merck to Participate in the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/DRIO/dariohealth-q3-2026-financial-results BiopharmaWatch en 2026-11-12T11:30:00.000Z DarioHealth Reports Third Quarter 2026 Financial Results: Year-over-Year Revenue Growth and Operating Expense Reduction https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-12T11:30:00.000Z Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-reports-third-quarter-2026-financial-results-provides-business BiopharmaWatch en 2026-11-12T11:03:00.000Z Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/BHST/bioharvest-q3-2026-financial-results-update BiopharmaWatch en 2026-11-12T11:00:00.000Z BioHarvest Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/RMTI/rockwell-medical-q3-2026-results BiopharmaWatch en 2026-11-12T11:00:00.000Z Rockwell Medical Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/EYE/national-vision-holdings-q3-2026-results BiopharmaWatch en 2026-11-12T11:00:00.000Z National Vision Holdings, Inc. Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BLTE/belite-bio-q3-2026-financial-results-update BiopharmaWatch en 2026-11-12T11:00:00.000Z Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/OGN/organon-phase-3-data-vtama-atopic-dermatitis BiopharmaWatch en 2026-11-12T10:00:00.000Z Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI https://www.biopharmawatch.com/news/GH/guardant-health-prices-convertible-senior-notes BiopharmaWatch en 2026-11-12T06:09:00.000Z Guardant Health Prices $500 Million Convertible Senior Notes Offering https://www.biopharmawatch.com/news/PEPG/pepgen-announces-pricing-public-offering BiopharmaWatch en 2026-11-12T03:22:00.000Z PepGen Announces Pricing of $125 Million Public Offering https://www.biopharmawatch.com/news/GLAS/glass-house-brands-change-auditor BiopharmaWatch en 2026-11-12T01:00:00.000Z Glass House Brands Announces Change of Auditor https://www.biopharmawatch.com/news/KOD/kodiak-sciences-investor-conferences-2026 BiopharmaWatch en 2026-11-11T23:43:00.000Z Kodiak Sciences to Present at Three Upcoming Investor Conferences https://www.biopharmawatch.com/news/NVAX/novavax-jefferies-london-healthcare-conference-2026 BiopharmaWatch en 2026-11-11T22:00:00.000Z Novavax to Participate in Jefferies London Healthcare Conference https://www.biopharmawatch.com/news/ADXN/addex-neurosterix-series-b-financing BiopharmaWatch en 2026-11-11T21:32:00.000Z Addex Spin-out Neurosterix Closes $105 Million Series B Financing https://www.biopharmawatch.com/news/PFE/pfizer-blackstone-funding-agreement-obesity-program BiopharmaWatch en 2026-11-11T21:30:00.000Z Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program https://www.biopharmawatch.com/news/CAH/cardinal-health-board-directors-approves-quarterly-dividend BiopharmaWatch en 2026-11-11T21:30:00.000Z Cardinal Health Board of Directors Approves Quarterly Dividend https://www.biopharmawatch.com/news/CSTL/castle-biosciences-piper-sandler-conference-2026 BiopharmaWatch en 2026-11-11T21:30:00.000Z Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference https://www.biopharmawatch.com/news/HSDT/solana-company-reports-q3-2026-results BiopharmaWatch en 2026-11-11T21:25:00.000Z Solana Company Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GH/guardant-health-offers-convertible-senior-notes BiopharmaWatch en 2026-11-11T21:17:00.000Z Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032 https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-11T21:15:00.000Z Nektar Therapeutics to Participate in Two Investor Conferences in November https://www.biopharmawatch.com/news/MLSS/milestone-scientific-third-quarter-2026-conference-call BiopharmaWatch en 2026-11-11T21:15:00.000Z Milestone Scientific Schedules Third Quarter 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/ALVO/alvotech-financial-results-september-2026 BiopharmaWatch en 2026-11-11T21:15:00.000Z Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update https://www.biopharmawatch.com/news/AIRS/airsculpt-nationwide-open-house-gift-body-confidence BiopharmaWatch en 2026-11-11T21:05:33.000Z AirSculpt Technologies Announces First-Ever Nationwide Open House Event, "The Gift of Body Confidence" https://www.biopharmawatch.com/news/IRTC/irhythm-200-million-share-repurchase-program BiopharmaWatch en 2026-11-11T21:05:00.000Z iRhythm Announces Approval of $200 Million Share Repurchase Program https://www.biopharmawatch.com/news/WGS/genedx-participate-upcoming-investor-conferences-20261111 BiopharmaWatch en 2026-11-11T21:05:00.000Z GeneDx to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ATEC/atec-announces-participation-upcoming-investor-conferences BiopharmaWatch en 2026-11-11T21:05:00.000Z ATEC Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ACOG/alpha-cognition-reports-q3-2026-results BiopharmaWatch en 2026-11-11T21:05:00.000Z Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update https://www.biopharmawatch.com/news/ONCY/oncolytics-clinical-supply-agreement-pelareorep-loqtorzi BiopharmaWatch en 2026-11-11T21:05:00.000Z Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma https://www.biopharmawatch.com/news/VANI/vivani-medical-q3-2026-financial-results-update BiopharmaWatch en 2026-11-11T21:05:00.000Z Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ICU/seastar-medical-q3-2026-financial-results BiopharmaWatch en 2026-11-11T21:05:00.000Z SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/SGP/spyglass-pharma-q3-2026-results-updates BiopharmaWatch en 2026-11-11T21:05:00.000Z SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/XAIR/beyond-air-financial-results-corporate-update-q3-2026 BiopharmaWatch en 2026-11-11T21:05:00.000Z Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/NSPR/inspiremd-third-quarter-2026-financial-results-timing BiopharmaWatch en 2026-11-11T21:05:00.000Z InspireMD Announces Updated Timing for Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ENGN/engn-bla-submission-detalimogene-legend-trial-results BiopharmaWatch en 2026-11-11T21:03:00.000Z enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC https://www.biopharmawatch.com/news/DCTH/delcath-systems-health-uncensored-dr-drew BiopharmaWatch en 2026-11-11T21:01:00.000Z Delcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer Treatment https://www.biopharmawatch.com/news/ENGN/engene-appoints-key-executives-regulatory-milestones BiopharmaWatch en 2026-11-11T21:01:00.000Z enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones https://www.biopharmawatch.com/news/LKFT/lakefront-biotherapeutics-financial-results-2026 BiopharmaWatch en 2026-11-11T21:01:00.000Z Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T21:01:00.000Z Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/PETV/petvivo-quarterly-report-november-2026 BiopharmaWatch en 2026-11-11T18:12:00.000Z PETVIVO HOLDINGS TO FILE QUARTERLY REPORT ON NOVEMBER 13, 2026; WELCOMES SHAREHOLDER QUESTIONS AND DIALOGUE https://www.biopharmawatch.com/news/MRNA/moderna-mnexspike-effectiveness-older-adults BiopharmaWatch en 2026-11-11T16:10:00.000Z Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older https://www.biopharmawatch.com/news/LLY/new-phase-3b-data-lilly-s-taltz-ixekizumab-zepbound-tirzepatide BiopharmaWatch en 2026-11-11T14:45:00.000Z New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity https://www.biopharmawatch.com/news/COSM/cosmos-health-us-ecommerce-update-october-2026 BiopharmaWatch en 2026-11-11T14:30:00.000Z Cosmos Health Provides U.S. E-Commerce Update for October 2026: Monthly Subscription Value Reaches $1.83 Million, Approximately $22 Million Annualized https://www.biopharmawatch.com/news/SINT/sintx-advances-sin-peek-3d-printing-orthopedic-implants BiopharmaWatch en 2026-11-11T14:00:25.000Z SINTX Technologies Advances SiN/PEEK 3D Printing Platform Toward Personalized Orthopedic Implant Commercialization https://www.biopharmawatch.com/news/APVO/aptevo-therapeutics-warrant-exercise-3-million BiopharmaWatch en 2026-11-11T14:00:00.000Z Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds https://www.biopharmawatch.com/news/PMCB/pharmacyte-biotech-reverse-stock-split BiopharmaWatch en 2026-11-11T14:00:00.000Z PharmaCyte Biotech, Inc. Announces Reverse Stock Split https://www.biopharmawatch.com/news/CVS/cvs-health-ai-technology-innovation-awards BiopharmaWatch en 2026-11-11T14:00:00.000Z CVS Health earns global recognition for industry-leading AI and technology innovation https://www.biopharmawatch.com/news/VNDA/nereus-goat-biscayne-bay-miami-art-week BiopharmaWatch en 2026-11-11T14:00:00.000Z NEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art Week https://www.biopharmawatch.com/news/NXGL/nexgel-noteholder-participation-recapitalization-funding BiopharmaWatch en 2026-11-11T14:00:00.000Z NEXGEL Announces Noteholder Participation in Strategic Recapitalization and Approximately $1.2 Million in New Capital Funding https://www.biopharmawatch.com/news/TPST/tempest-therapeutics-licenses-senlang-car-t-platform BiopharmaWatch en 2026-11-11T13:53:00.000Z Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate https://www.biopharmawatch.com/news/GH/guardant-health-new-epigenomic-applications BiopharmaWatch en 2026-11-11T13:46:00.000Z Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-virtual-investor-segment-vatnak-vat-ho BiopharmaWatch en 2026-11-11T13:44:00.000Z Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho https://www.biopharmawatch.com/news/NTHI/neonc-fda-meeting-neon100-accelerated-approval BiopharmaWatch en 2026-11-11T13:37:00.000Z FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track https://www.biopharmawatch.com/news/GMAB/genmab-s-published-articles-association-20261111 BiopharmaWatch en 2026-11-11T13:34:02.000Z Genmab A/S has published its Articles of Association https://www.biopharmawatch.com/news/AGPU/axe-compute-q3-2026-financial-results-call BiopharmaWatch en 2026-11-11T13:30:33.000Z Axe Compute to Host Q3 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/PTIX/protagenic-therapeutics-private-placement-pt00114 BiopharmaWatch en 2026-11-11T13:30:00.000Z Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder https://www.biopharmawatch.com/news/HCA/hca-healthcare-best-employer-veterans BiopharmaWatch en 2026-11-11T13:30:00.000Z HCA Healthcare Named a Best Employer for Veterans by Military Times for Seventh Consecutive Year https://www.biopharmawatch.com/news/IBRX/us-survey-military-veterans-nmibc-barriers-care BiopharmaWatch en 2026-11-11T13:30:00.000Z New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care https://www.biopharmawatch.com/news/CERS/cerus-corporation-participate-craig-hallum-conference BiopharmaWatch en 2026-11-11T13:30:00.000Z Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T13:30:00.000Z Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/PRGO/perrigo-jefferies-miami-consumer-conference BiopharmaWatch en 2026-11-11T13:30:00.000Z Perrigo to Attend the Jefferies Miami Consumer Conference https://www.biopharmawatch.com/news/CAI/caris-launches-study-challenge-testing-myeloid-malignancies BiopharmaWatch en 2026-11-11T13:30:00.000Z Caris Launches Landmark Study to Challenge Fragmented Testing in Myeloid Malignancies https://www.biopharmawatch.com/news/ICCM/icecure-medical-q3-2026-results BiopharmaWatch en 2026-11-11T13:30:00.000Z IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026 https://www.biopharmawatch.com/news/WVE/wave-life-sciences-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T13:30:00.000Z Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T13:30:00.000Z Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/RARE/ultragenyx-investor-conferences-london-november-2026 BiopharmaWatch en 2026-11-11T13:30:00.000Z Ultragenyx to Participate at Investor Conferences in London https://www.biopharmawatch.com/news/RLYB/rallybio-reverse-stock-split-correction BiopharmaWatch en 2026-11-11T13:15:00.000Z Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo https://www.biopharmawatch.com/news/VBIO/valion-bio-entolimod-national-security-conference BiopharmaWatch en 2026-11-11T13:10:00.000Z Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference https://www.biopharmawatch.com/news/INO/inovio-participate-investor-conferences BiopharmaWatch en 2026-11-11T13:05:00.000Z INOVIO to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/SPAI/safe-pro-awarded-ai-demining-contract-ukraine BiopharmaWatch en 2026-11-11T13:02:16.000Z Safe Pro Awarded Artificial Intelligence Powered Demining Contract by Ukrainian Deminers Association Under United Nations Mine Action Service (UNMAS) Program https://www.biopharmawatch.com/news/NTHI/neonc-fda-meeting-ne100-accelerated-approval BiopharmaWatch en 2026-11-11T13:00:40.000Z NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100 https://www.biopharmawatch.com/news/CLGN/lightsolver-unveil-first-public-demonstration-sc26 BiopharmaWatch en 2026-11-11T13:00:00.000Z LightSolver to Unveil the First Public Demonstration of its All-Optical Computer at SC26 https://www.biopharmawatch.com/news/RXRX/recursion-participate-upcoming-investor-conferences-20261111 BiopharmaWatch en 2026-11-11T13:00:00.000Z Recursion to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BIAF/bioaffinity-record-testing-volume-october BiopharmaWatch en 2026-11-11T13:00:00.000Z bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test https://www.biopharmawatch.com/news/TWST/twist-bioscience-inducement-grants-nasdaq BiopharmaWatch en 2026-11-11T13:00:00.000Z Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/TRLV/trulieve-november-2026-event-participation BiopharmaWatch en 2026-11-11T13:00:00.000Z Trulieve Announces November 2026 Event Participation https://www.biopharmawatch.com/news/AMGN/amgen-positive-phase-3-results-dazodalibep-sjogrens-disease BiopharmaWatch en 2026-11-11T13:00:00.000Z AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE https://www.biopharmawatch.com/news/ATNM/actinium-radianz-trial-atnm-400-enrollment BiopharmaWatch en 2026-11-11T13:00:00.000Z Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy https://www.biopharmawatch.com/news/BIOA/bioage-labs-present-upcoming-investor-conferences BiopharmaWatch en 2026-11-11T13:00:00.000Z BioAge Labs to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-jill-quigley-board-appointment BiopharmaWatch en 2026-11-11T13:00:00.000Z Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board https://www.biopharmawatch.com/news/HUMA/humacyte-atev-veithsymposium-2026 BiopharmaWatch en 2026-11-11T13:00:00.000Z Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026 https://www.biopharmawatch.com/news/ATYR/atyr-pharma-investor-conferences-2026 BiopharmaWatch en 2026-11-11T13:00:00.000Z aTyr Pharma to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-inc-present-jefferies-global-healthcare-conference-london BiopharmaWatch en 2026-11-11T13:00:00.000Z Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/TEVA/teva-rd-day-innovative-pipeline-growth BiopharmaWatch en 2026-11-11T12:30:00.000Z Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030 https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-november-investor-conferences BiopharmaWatch en 2026-11-11T12:30:00.000Z Faeth Therapeutics to Participate in Upcoming November Investor Conferences https://www.biopharmawatch.com/news/ZTS/zoetis-usda-license-cytopoint-plus BiopharmaWatch en 2026-11-11T12:30:00.000Z Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis https://www.biopharmawatch.com/news/LYCA/lycia-therapeutics-presentation-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T12:30:00.000Z Lycia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/BBIO/bridgebio-acoramidis-data-symposium-2026 BiopharmaWatch en 2026-11-11T12:30:00.000Z BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026 https://www.biopharmawatch.com/news/PYPD/polypid-corporate-update-q3-2026-results BiopharmaWatch en 2026-11-11T12:30:00.000Z PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-investor-conference-november-2026 BiopharmaWatch en 2026-11-11T12:30:00.000Z Dyne Therapeutics to Participate in Upcoming Investor Conference https://www.biopharmawatch.com/news/INKT/mink-therapeutics-q3-2026-results-agent-797 BiopharmaWatch en 2026-11-11T12:30:00.000Z MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies https://www.biopharmawatch.com/news/TLRY/breckenridge-distillery-2-mile-high-whiskey-club BiopharmaWatch en 2026-11-11T12:00:33.000Z Whiskey You Won't Find on Shelves: Breckenridge Distillery Launches the 2 Mile High Whiskey Club https://www.biopharmawatch.com/news/ULS/ul-solutions-announces-quarterly-dividend BiopharmaWatch en 2026-11-11T12:00:00.000Z UL Solutions Announces Quarterly Dividend https://www.biopharmawatch.com/news/CSTL/decisiondx-melanoma-data-sdpa-dermato-onco2026 BiopharmaWatch en 2026-11-11T12:00:00.000Z DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging https://www.biopharmawatch.com/news/CDT/cdt-human-skin-studies-vitiligo-tapinarof BiopharmaWatch en 2026-11-11T12:00:00.000Z CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo https://www.biopharmawatch.com/news/KARD/kardigan-participate-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-11T12:00:00.000Z Kardigan to Participate in the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/INMD/inmode-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-11T12:00:00.000Z InMode Reports Third Quarter 2026 Financial Results: Quarterly GAAP Revenues of $92.1 Million; Reaffirms Full-Year 2026 Financial Outlook https://www.biopharmawatch.com/news/GNPX/genprex-diabetes-gene-therapy-symposium BiopharmaWatch en 2026-11-11T12:00:00.000Z Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium https://www.biopharmawatch.com/news/ACIU/ac-immune-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-11T12:00:00.000Z AC Immune to Present at Jefferies Global Healthcare Conference 2026 https://www.biopharmawatch.com/news/NKTX/nkarta-nkx019-safety-data-acr-convergence-2026 BiopharmaWatch en 2026-11-11T12:00:00.000Z Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026 https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-11-11T12:00:00.000Z Hemab Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-arati-rao-cmo-appointment BiopharmaWatch en 2026-11-11T12:00:00.000Z Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-preservative-free-ketamine-launch BiopharmaWatch en 2026-11-11T12:00:00.000Z NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage https://www.biopharmawatch.com/news/ARVN/arvinas-present-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-11T12:00:00.000Z Arvinas to Present at Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/QTTB/q32-bio-2026-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-11T11:59:00.000Z Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/VTRS/viatris-participate-upcoming-investor-conferences-20261111 BiopharmaWatch en 2026-11-11T11:59:00.000Z Viatris to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/TFX/teleflex-present-jefferies-global-healthcare-conference-london BiopharmaWatch en 2026-11-11T11:30:00.000Z Teleflex to Present at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/CMPS/compass-pathways-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-11T11:30:00.000Z Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-jefferies-conference-2026 BiopharmaWatch en 2026-11-11T11:00:00.000Z Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/NVO/novo-nordisk-200-million-world-diabetes-foundation BiopharmaWatch en 2026-11-11T09:30:00.000Z Novo commits USD 200 million over 10 years to support the World Diabetes Foundation to strengthen diabetes prevention and care https://www.biopharmawatch.com/news/TLX/telix-participate-ubs-global-biopharma-conference BiopharmaWatch en 2026-11-11T07:00:00.000Z Telix to Participate in UBS Global Biopharma Conference https://www.biopharmawatch.com/news/PHAR/pharming-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-11T07:00:00.000Z Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London